The predictive value of plasma cystatin C for acute coronary syndrome treated with percutaneous coronary intervention

T.-W. Sun, Q.-Y. Xu, H.-M. Yao, X.-J. Zhang, Q.. Wu, J.-Y. Zhang, L. Li, Y.-Z. Zhang, Q.-C. Kan, F.-X. Guan, Lexin Wang

Research output: Contribution to journalArticle

6 Citations (Scopus)

Abstract

BackgroundThis study was designed to evaluate the value of plasma cystatin C in predicting adverse cardiac events after percutaneous coronary intervention (PCI) for acute coronary syndrome (ACS).MethodsA total of 605 patients (404 male, mean age 60.4 ± 10.6 years) with ACS underwent successful PCI. Patients were divided into 4 groups according to the level of cystatin C, which was measured before the PCI: Q1 (<1.02 mg/L), Q2 (1.02-1.16 mg/L), Q3 (1.17-1.34 mg/L), and Q4 ('1.35 mg/L).ResultsAfter a follow-up of 14.3 ± 1.7 months, the incidence of mortality, nonfatal myocardial infarction, and target lesion revascularization in the Q2, Q3, and Q4 groups was higher than in the Q1 group (P < .001). The incidence of heart failure in the Q3 and Q4 groups was higher than in the Q1 group (P < .05). Multivariate Cox regression analysis showed that cystatin C elevation was an independent predictor of major adverse cardiac events. The cumulative survival rate of the Q3 and Q4 groups was lower than in the Q1 group (P < .001).ConclusionHigh plasma cystatin C concentration is an independent predictor of major adverse cardiac events in patients with ACS treated with PCI.
Original languageEnglish
Pages (from-to)456-62
Number of pages7
JournalHeart and Lung: Journal of Acute and Critical Care
Volume41
Issue number5
DOIs
Publication statusPublished - 2012

Fingerprint

Cystatin C
Percutaneous Coronary Intervention
Acute Coronary Syndrome
Incidence
Survival Rate
Heart Failure
Myocardial Infarction
Regression Analysis
Mortality

Cite this

Sun, T.-W. ; Xu, Q.-Y. ; Yao, H.-M. ; Zhang, X.-J. ; Wu, Q.. ; Zhang, J.-Y. ; Li, L. ; Zhang, Y.-Z. ; Kan, Q.-C. ; Guan, F.-X. ; Wang, Lexin. / The predictive value of plasma cystatin C for acute coronary syndrome treated with percutaneous coronary intervention. In: Heart and Lung: Journal of Acute and Critical Care. 2012 ; Vol. 41, No. 5. pp. 456-62.
@article{b8016809fc6c4c329f1b2fb2384d1a11,
title = "The predictive value of plasma cystatin C for acute coronary syndrome treated with percutaneous coronary intervention",
abstract = "BackgroundThis study was designed to evaluate the value of plasma cystatin C in predicting adverse cardiac events after percutaneous coronary intervention (PCI) for acute coronary syndrome (ACS).MethodsA total of 605 patients (404 male, mean age 60.4 ± 10.6 years) with ACS underwent successful PCI. Patients were divided into 4 groups according to the level of cystatin C, which was measured before the PCI: Q1 (<1.02 mg/L), Q2 (1.02-1.16 mg/L), Q3 (1.17-1.34 mg/L), and Q4 ('1.35 mg/L).ResultsAfter a follow-up of 14.3 ± 1.7 months, the incidence of mortality, nonfatal myocardial infarction, and target lesion revascularization in the Q2, Q3, and Q4 groups was higher than in the Q1 group (P < .001). The incidence of heart failure in the Q3 and Q4 groups was higher than in the Q1 group (P < .05). Multivariate Cox regression analysis showed that cystatin C elevation was an independent predictor of major adverse cardiac events. The cumulative survival rate of the Q3 and Q4 groups was lower than in the Q1 group (P < .001).ConclusionHigh plasma cystatin C concentration is an independent predictor of major adverse cardiac events in patients with ACS treated with PCI.",
keywords = "Acute coronary syndrome, Cystatin C, Major adverse cardiac events, Percutaneous coronary intervention, Prognosis",
author = "T.-W. Sun and Q.-Y. Xu and H.-M. Yao and X.-J. Zhang and Q.. Wu and J.-Y. Zhang and L. Li and Y.-Z. Zhang and Q.-C. Kan and F.-X. Guan and Lexin Wang",
note = "Imported on 12 Apr 2017 - DigiTool details were: Journal title (773t) = Heart and Lung: the journal of acute and critical care. ISSNs: 0147-9563;",
year = "2012",
doi = "10.1016/j.hrtlng.2012.04.007",
language = "English",
volume = "41",
pages = "456--62",
journal = "Heart and Lung: Journal of Acute and Critical Care",
issn = "0147-9563",
publisher = "Mosby Inc.",
number = "5",

}

The predictive value of plasma cystatin C for acute coronary syndrome treated with percutaneous coronary intervention. / Sun, T.-W.; Xu, Q.-Y.; Yao, H.-M.; Zhang, X.-J.; Wu, Q..; Zhang, J.-Y.; Li, L.; Zhang, Y.-Z.; Kan, Q.-C.; Guan, F.-X.; Wang, Lexin.

In: Heart and Lung: Journal of Acute and Critical Care, Vol. 41, No. 5, 2012, p. 456-62.

Research output: Contribution to journalArticle

TY - JOUR

T1 - The predictive value of plasma cystatin C for acute coronary syndrome treated with percutaneous coronary intervention

AU - Sun, T.-W.

AU - Xu, Q.-Y.

AU - Yao, H.-M.

AU - Zhang, X.-J.

AU - Wu, Q..

AU - Zhang, J.-Y.

AU - Li, L.

AU - Zhang, Y.-Z.

AU - Kan, Q.-C.

AU - Guan, F.-X.

AU - Wang, Lexin

N1 - Imported on 12 Apr 2017 - DigiTool details were: Journal title (773t) = Heart and Lung: the journal of acute and critical care. ISSNs: 0147-9563;

PY - 2012

Y1 - 2012

N2 - BackgroundThis study was designed to evaluate the value of plasma cystatin C in predicting adverse cardiac events after percutaneous coronary intervention (PCI) for acute coronary syndrome (ACS).MethodsA total of 605 patients (404 male, mean age 60.4 ± 10.6 years) with ACS underwent successful PCI. Patients were divided into 4 groups according to the level of cystatin C, which was measured before the PCI: Q1 (<1.02 mg/L), Q2 (1.02-1.16 mg/L), Q3 (1.17-1.34 mg/L), and Q4 ('1.35 mg/L).ResultsAfter a follow-up of 14.3 ± 1.7 months, the incidence of mortality, nonfatal myocardial infarction, and target lesion revascularization in the Q2, Q3, and Q4 groups was higher than in the Q1 group (P < .001). The incidence of heart failure in the Q3 and Q4 groups was higher than in the Q1 group (P < .05). Multivariate Cox regression analysis showed that cystatin C elevation was an independent predictor of major adverse cardiac events. The cumulative survival rate of the Q3 and Q4 groups was lower than in the Q1 group (P < .001).ConclusionHigh plasma cystatin C concentration is an independent predictor of major adverse cardiac events in patients with ACS treated with PCI.

AB - BackgroundThis study was designed to evaluate the value of plasma cystatin C in predicting adverse cardiac events after percutaneous coronary intervention (PCI) for acute coronary syndrome (ACS).MethodsA total of 605 patients (404 male, mean age 60.4 ± 10.6 years) with ACS underwent successful PCI. Patients were divided into 4 groups according to the level of cystatin C, which was measured before the PCI: Q1 (<1.02 mg/L), Q2 (1.02-1.16 mg/L), Q3 (1.17-1.34 mg/L), and Q4 ('1.35 mg/L).ResultsAfter a follow-up of 14.3 ± 1.7 months, the incidence of mortality, nonfatal myocardial infarction, and target lesion revascularization in the Q2, Q3, and Q4 groups was higher than in the Q1 group (P < .001). The incidence of heart failure in the Q3 and Q4 groups was higher than in the Q1 group (P < .05). Multivariate Cox regression analysis showed that cystatin C elevation was an independent predictor of major adverse cardiac events. The cumulative survival rate of the Q3 and Q4 groups was lower than in the Q1 group (P < .001).ConclusionHigh plasma cystatin C concentration is an independent predictor of major adverse cardiac events in patients with ACS treated with PCI.

KW - Acute coronary syndrome

KW - Cystatin C

KW - Major adverse cardiac events

KW - Percutaneous coronary intervention

KW - Prognosis

U2 - 10.1016/j.hrtlng.2012.04.007

DO - 10.1016/j.hrtlng.2012.04.007

M3 - Article

VL - 41

SP - 456

EP - 462

JO - Heart and Lung: Journal of Acute and Critical Care

JF - Heart and Lung: Journal of Acute and Critical Care

SN - 0147-9563

IS - 5

ER -